comparemela.com

Latest Breaking News On - Elderly relapsed - Page 7 : comparemela.com

Actinium Pharmaceuticals, Inc to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

- Updated Phase 3 SIERRA data to be presented in an oral presentation by Boglarka Gyurkocza, M.D., SIERRA trial investigator from Memorial Sloan Kettering.

United statesSalt lake citySalt palace convention centerHans vitzthumBoglarka gyurkoczaSandesh sethJames foranAvinash desaiLifesci advisorsUniversity of texas md anderson cancer centerAmerican society for transplantationInternational blood marrow transplant researchExchange commissionAstellas pharma incActinium pharmaceuticals incEuropean medicines agency

Actinium Pharmaceuticals, Inc and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for.

United statesSandesh sethHans vitzthumAnders edvellLifesci advisorsShadow lake groupExchange commissionAstellas pharma incActinium pharmaceuticals incEuropean medicines agencyCommittee for medicinal products human useEpicentrx incMemorial sloan kettering cancer centerFred hutchinson cancer research centerMiddle eastActinium pharmaceuticals

Actinium Pharmaceuticals, Inc and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.

Astellas pharmaEpicentrx cyEpicentrx rrxTonyr reidSandesh sethHans vitzthumLifesci advisorsTaft communicationsSociety for immunotherapy of cancerExchange commissionAstellas pharma incActinium pharmaceuticals incEpicentrx incMemorial sloan kettering cancer centerPrnewswire actinium pharmaceuticals incSan diego based

Actinium Pharmaceuticals, Inc and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.

Astellas pharmaEpicentrx cyEpicentrx rrxTonyr reidSandesh sethHans vitzthumLifesci advisorsTaft communicationsSociety for immunotherapy of cancerExchange commissionAstellas pharma incActinium pharmaceuticals incEpicentrx incMemorial sloan kettering cancer centerPrnewswire actinium pharmaceuticals incSan diego based

Actinium Pharmaceuticals, Inc Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.

Hans vitzthumMary chenHelen kotanidesPreclinical developmentLifesci advisorsExchange commissionMonths of development alpha emitting therapiesAstellas pharma incActinium pharmaceuticals incTranslational researchClinical developmentMemorial sloan kettering cancer centerActinium pharmaceuticalsTargeted radiopharmaceuticals summitTargeted radiopharmaceuticalsAlpha emitting therapies

vimarsana © 2020. All Rights Reserved.